We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Teijin Pharma and Scynexis Sign Research Agreement
News

Teijin Pharma and Scynexis Sign Research Agreement

Teijin Pharma and Scynexis Sign Research Agreement
News

Teijin Pharma and Scynexis Sign Research Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Teijin Pharma and Scynexis Sign Research Agreement "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Teijin Pharma Limited, a wholly owned subsidiary of Teijin Limited, and Scynexis have signed an agreement under which Scynexis will provide comprehensive medicinal and analytical chemistry services to Teijin Pharma's research programs.

The agreement provides Teijin Pharma with dedicated chemistry resources including a highly experienced Scynexis medicinal chemistry team backed by proprietary, innovative technologies.

“Scynexis is pleased to work with Teijin Pharma in its novel drug discovery and development efforts and to have Teijin Pharma as one of Scynexis' valued customers in the important Japanese market,” said Yves Ribeill, President and Chief Executive Officer of Scynexis.

“Scynexis has now firmly established relationships in Japan, Europe and the U.S. confirming its ability to deliver valuable capabilities and technologies to a wide range of customers.”

Advertisement